1. Valent P., Akin C., Metcalfe D.D.: Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts. Blood 2017, 129, 1420-1427.
2.
Méni C., Bruneau J., Georgin-Lavialle S., Le Saché de Peufeilhoux L., Damaj G., Hadj-Rabia S., et al.: Paediatric mastocytosis: a systematic review of 1747 cases. Br J Dermatol 2015, 172, 642-651.
3.
Hannaford R., Rogers M.: Presentation of cutaneous mastocytosis in 173 children. Australas J Dermatol 2001, 42, 15-21.
4.
Akin C., Valent P., Metcalfe D.D.: Mast cell activation syndrome: proposed diagnostic criteria. J Allergy Clin Immunol 2010, 126, 1099-1104.
5.
Arock M., Akin C., Hermine O., Valent P.: Current treatment options in patients with mastocytosis: status in 2015 and future perspectives. Eur J Haematol 2015, 94, 474-490.
6.
Siebenhaar F., Akin C., Bindslev-Jensen C., Maurer M., Broesby-Olsen S.: Treatment strategies in mastocytosis. Immunol Allergy Clin North Am 2014, 34, 433-447.
7.
Castells M., Butterfield J.: Mast cell activation syndrome and mastocytosis: initial treatment options and long-term management. J Allergy Clin Immunol Pract 2019, 7, 1097-1106.
8.
Czarny J., Lange M., Ługowska-Umer H., Nowicki R.J.: Cutaneous mastocytosis treatment: strategies, limitations and perspectives. Adv Dermatol Allergol 2018, 35, 541-545.
9.
Morren M.A., Hoppé A., Renard M., Debiec-Rychter M., Uyttebroeck A., Dubreuil P., et al.: Imatinib mesylate in the treatment of diffuse cutaneous mastocytosis. J Pediatr 2013, 162, 205-207.
10.
Schaffer J.V.: Pediatric mastocytosis: recognition and management. Am J Clin Dermatol 2021, 22, 205-220.
11.
Liu M.M., Kohn L.A., Roach G.D., Sun G., Garcia-Lloret M.I., Butte M.J.: Treatment of systemic mastocytosis in an infant with midostaurin. J Allergy Clin Immunol Pract 2019, 7, 2929-2931.
12.
Sumbly V., Landry I., Iqbal S., Bhatti Z., Alshamam M.S., Ashfaq S., et al.: The role of avapritinib for the treatment of systemic mastocytosis. Cureus 2021, 13, e18385.
13.
Degenfeld-Schonburg L., Gamperl S., Stefanzl G., Schruef A.K., Sadovnik I., Bauer K., et al.: Antineoplastic efficacy profiles of avapritinib and nintedanib in KIT D816V+ systemic mastocytosis: a preclinical study. Am J Cancer Res 2023, 13, 355-378.
14.
Hartmann K., Escribano L., Grattan C., Brockow K., Carter M.C., Alvarez-Twose I., et al.: Cutaneous manifestations in patients with mastocytosis: consensus report of the European Competence Network on Mastocytosis, The American Academy of Allergy, Asthma & Immunology, and the European Academy of Allergology and Clinical Immunology. J Allergy Clin Immunol 2016, 137, 35-45.
15.
Lange M., Hartmann K., Carter M.C., Siebenhaar F., Alvarez-Twose I., Torrado I., et al.: Molecular background, clinical features and management of pediatric mastocytosis: status 2021. Int J Mol Sci 2021, 22, 2586.
16.
Lange M., Niedoszytko M., Nedoszytko B., Łata J., Trzeciak M., Biernat W.: Diffuse cutaneous mastocytosis: analysis of 10 cases and a brief review of the literature. J Eur Acad Dermatol Venereol 2012, 26, 1565-1571.
17.
Renke J., Irga-Jaworska N., Lange M.: Pediatric and hereditary mastocytosis. Immunol Allergy Clin North Am 2023, 43, 665-679.
18.
Ługowska-Umer H., Czarny J., Rydz A., Nowicki R.J., Lange M.: Current challenges in the diagnosis of pediatric cutaneous mastocytosis. Diagnostics (Basel) 2023, 13, 3583.
19.
Hoffmann K.M., Moser A., Lohse P., Winkler A., Binder B., Sovinz P., et al.: Successful treatment of progressive cutaneous mastocytosis with imatinib in a 2-year-old boy carrying a somatic KIT mutation. Blood 2008, 112, 1655-1657.
20.
Dhyani P., Quispe C., Sharma E., Bahukhandi A., Sati P., Attri D.C., et al.: Anticancer potential of alkaloids: a key emphasis to colchicine, vinblastine, vincristine, vindesine, vinorelbine and vincamine. Cancer Cell Int 2022, 22, 206.
21.
Piris-Villaespesa M., Alvarez-Twose I.: Systemic mastocytosis: following the tyrosine kinase inhibition roadmap. Front Pharmacol 2020, 11, 443.
22.
Lübke J., Naumann N., Kluger S., Schwaab J., Metzgeroth G., Evans E., et al.: Inhibitory effects of midostaurin and avapritinib on myeloid progenitors derived from patients with KIT D816V positive advanced systemic mastocytosis. Leukemia 2019, 33, 1195-1205.
23.
Olteanu E.G., Bataneant M., Puiu M., Chirita-Emandi A.: When mast cells run amok: a comprehensive review and case study on severe neonatal diffuse cutaneous mastocytosis. Genes (Basel) 2023, 14, 2021.
24.
Shah P.Y., Sharma V., Worobec A.S., Metcalfe D.D., Zwick D.C.: Congenital bullous mastocytosis with myeloproliferative disorder and c-kit mutation. J Am Acad Dermatol 1998, 39, 119-121.
25.
Heide R., Zuidema E., Beishuizen A., Den Hollander J.C., Van Gysel D., Seyger M.M., et al.: Clinical aspects of diffuse cutaneous mastocytosis in children: two variants. Dermatology 2009, 219, 309-315.
26.
Chaudhary N., Shapiro N., Bhutada A., Rastogi S.: c-KIT-positive fatal diffuse cutaneous mastocytosis with systemic manifestations in a neonate. J Pediatr Hematol Oncol 2019, 41, e338-e340.
27.
Jenkinson H.A., Lundgren A.D., Carter M.C., Diaz L.Z., Levy M.L.: Management of a neonate with diffuse cutaneous mastocytosis: case report and literature review. Pediatr Dermatol 2019, 36, 486-489.
